Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...

The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

Both moves have shown up in margin expansion. Insulet is currently enjoying adoption of its Omnipod Dash, which allows for access to personal blood glucose and insulin readings from the pump to a ...

A mother measuring her daughter’s glucose In children with type 1 diabetes, the Omnipod hybrid closed-loop personal model system was safe and performed well. ORLANDO — In children aged between 6 and ...

Two studies demonstrated that the Omnipod Horizon algorithm performed well in response to meal challenges and exercise in 24 adults with type 1 diabetes. Results showed strong blood glucose control ...

The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.

Insulet's investigational Omnipod 5 automated insulin delivery system improves glycemic control in people with type 1 diabetes as young as 2 years of age, new data suggest. The Omnipod 5 system ...

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of age ...

Insulet Corp. received FDA clearance for its Omnipod 5 closed-loop automated insulin delivery (AID) system for patients aged six and older who have type 1 diabetes on Friday, Jan. 28, making it the ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the commercial launch of its ...